Skip to content

News & Events

Ansa Biotechnologies Appoints Jason T. Gammack as CEO

    Gammack is joining the company as it completes its early access program and prepares for a full commercial launch of its rapid enzymatic synthesis for complex clonal genes and gene fragments. Founding CEO Dan Lin-Arlow, PhD, will remain with the company and transition to a new position as chief scientific officer.

    View the press release.

    The Global Synthetic Biology Conference

      May 6-9, 2024 | Booth #312
      San Jose Convention Center

      We look forward to meeting you at the Global Synthetic Biology meeting (formerly SynBioBeta). Visit us at booth #312 to explore Ansa’s groundbreaking enzymatic DNA synthesis technology. Don’t miss Ansa’s Chief Scientific Officer, Dan Lin-Arlow, presenting ‘Reshaping Biology with the Power of Enzymatic DNA Synthesis’ in a Spotlight session. Join our interactive Breakout session where industry thought leaders will share their thoughts on the future of DNA synthesis, where innovation intersects with practical solutions to rapidly and reliably synthesize long DNA without sequence limitations. The session will include a panel discussion and Q&A. Join us in unlocking the potential of enzymatic DNA synthesis to revolutionize your research.
      https://www.synbiobeta.com/attend/conference-2024

      Long DNA for Difficult Applications – Dan Lin-Arlow, CEO

        CEO Dan Lin-Arlow discusses Ansa’s groundbreaking de novo synthesis of the world’s longest oligo and their proprietary method in a podcast with Theral Timpson on the Mendelspod podcast. Explore the challenges of synthesizing long DNA, the impact of computation and AI in DNA synthesis, and more. Subscribe to Mendelspod to listen to the full podcast.